Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results

Artiva Biotherapeutics (NASDAQ:ARTV) announced its earnings results on Tuesday. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24), Zacks reports.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV traded down $0.49 on Thursday, reaching $11.21. 7,356 shares of the company’s stock traded hands, compared to its average volume of 138,614. The business has a 50 day moving average of $12.60. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ARTV shares. Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating and a $21.00 price target on the stock. Wedbush restated an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday. Cantor Fitzgerald started coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target for the company. Finally, TD Cowen initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $21.25.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.